Study summary

Momelotinib helped spleen and anemia at the same time more often than ruxolitinib

SIMPLIFY-1 analysis · Phase 3 analysis, people with hemoglobin under 10 g/dL · Published February 2026, Clinical Lymphoma, Myeloma and Leukemia; FDA approved 2023

What was tested

An analysis of the SIMPLIFY-1 trial of momelotinib, a JAK inhibitor that also blocks a protein (ACVR1) that drives anemia, against ruxolitinib, in people with myelofibrosis and anemia.

What they found

• Spleen shrinkage plus transfusion independence at 24 weeks: 27% vs 7%.
• Becoming transfusion-independent was linked to longer survival (hazard ratio 0.25).

What it means

Supports momelotinib as the preferred JAK inhibitor for people whose main problem is anemia.